

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **LI et al.**

Examiner: **To Be Assigned**

Serial No.: **To Be Assigned**

Group Art Unit: **To Be Assigned**

Filed: **Herewith**

Title: **METHOD FOR ASSAYING COMPOUNDS
THAT DECREASE THE ACTIVITY OF
POLY(ADP-RIBOSE)-POLYMERASE (PARP)**

POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop Patent Applications
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I, Ross J. Oehler, an Officer of Aventis Pharmaceuticals Inc., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

By:



Ross J. Oehler

Title:

Assistant Secretary

Date:

8/27/03

Address correspondence and telephone calls to:
William C. Coppola, Reg. No. 41,686
Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3800
Telefax (908) 231-2626

DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR ASSAYING COMPOUNDS THAT DECREASE THE ACTIVITY OF POLY(ADP-RIBOSE)-POLYMERASE (PARP)

and the specification of which ☒ is attached hereto (Aventis Docket No. **USAV2002/0121USNP**)
(check one) ☐ was filed on _____ as U.S. Application Number _____
and was amended on _____ (if applicable).
☐ was described and claimed in PCT Int'l Application Number _____ filed on _____
and as amended under PCT Article 19 on _____ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

☐ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority:	0301628.4 Number	GB Country	24/01/2003 Day/Month/Year Filed
----------------------	----------------------------	----------------------	---

Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed
-------------------------------	--------	---------	----------------------

☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

60/412,136 Number	09/19/2002 Filing Date
-----------------------------	----------------------------------

☐ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application Serial No.	Filing Date	Status (Patented, Pending)
------------------------	-------------	----------------------------

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☐ Additional names and signatures are attached.

1. Full name: **Zhuyin Julie LI**

Signature: _____

Date: _____

Country of Citizenship: **United States**

Residence: **Flemington, New Jersey**
(City and State/City and Country only)

P. O. Address: **12 Hastings Place**
Flemington, NJ 08822

2. Full name: **Shujaath MEHDI**

Signature: _____

Date: _____

Country of Citizenship: **United States**

Residence: **Manville, New Jersey**
(City and State/City and Country only)

P. O. Address: **43 North 14th Avenue, Apt. 2**
Manville, NJ 08835

3. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

5. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

4. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

6. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)

P. O. Address: _____

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3800
Telefax (908) 231-2626

Aventis Docket No. **USAV2002/0121USNP**